Market Overview

UPDATE: Credit Suisse Initiates Sequenom at Underperform on Competitive Challenges

Related SQNM
Here's Why Sequenom Surged 20% After Tuesday's Market Close
Sequenom Names Dirk van den Boom as President and CEO

Credit Suisse initiated coverage on Sequenom (NASDAQ: SQNM) with an Underperform rating and a $4 price target.

Credit Suisse noted, "While we are excited about the scientific advance and volume potential that noninvasive prenatal genetic tests, including Sequenom's MaterniT21 PLUS, offer, we are concerned that the aggressive competitive dynamics we are already seeing (most notably with pricing) will limit the commercial potential of the test and cause the stock to underperform the rest of our coverage universe over the next 12 months."

Sequenom closed at $3.70 on Monday.

Latest Ratings for SQNM

Mar 2016Ladenburg ThalmannUpgradesSellNeutral
Sep 2015JefferiesDowngradesBuyHold
Sep 2015William BlairDowngradesMarket Perform

View More Analyst Ratings for SQNM
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Initiation Pre-Market Outlook Analyst Ratings


Related Articles (SQNM)

View Comments and Join the Discussion!